E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
congenital vascular malformation : Vascular malformations
can involve lymphatic vessels, capillaries, veins and arteries or even combinations. These vascular
malformations are present at birth and grow with the child. |
|
E.1.1.1 | Medical condition in easily understood language |
congenital vascular malformation that cannot sufficiently be treated with standard methods like pain medication, surgery or embolisation |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | HLT |
E.1.2 | Classification code | 10047091 |
E.1.2 | Term | Vascular malformations and acquired anomalies |
E.1.2 | System Organ Class | 100000005125 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10047090 |
E.1.2 | Term | Vascular malformation peripheral |
E.1.2 | System Organ Class | 100000158692 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10070181 |
E.1.2 | Term | Gastrointestinal vascular malformation |
E.1.2 | System Organ Class | 10017947 - Gastrointestinal disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10074979 |
E.1.2 | Term | Vascular malformation |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To investigate whether Sirolimus results in a significant and clinically relevant reduction of pain and an
improved quality of life in patients with untreatable vascular malformations. |
|
E.2.2 | Secondary objectives of the trial |
What length of therapy is required to have and maintain adequate pain reduction?
Will response to Sirolimus prolong after stop treatment or will there be a rebound?
Will Sirolimus only have effect on pain reduction or will Sirolimus also inhibit growth/progression of the
vascular malformation or even lead to reduction of the size of the vascular malformation?
Which long term consequences can be observed after treatment with Sirolimus e.g. in children?
Are there genetic factors in the vascular malformation that can predict outcome of treatment with Sirolimus?
Will Sirolimus lead to a more cost-effective treatment for this patient group? |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Diagnosis of Congenital venous malformation, or lymphatic malformation or combined.
• Age between 1-60 years.
• Patients (or legal guardians for children) have to be able to sign the informed consent
• Patients are either refractory to standard care such as medical treatment (low molecular weight heparines, pain medication etc.), surgical resection and/or sclerotherapy/embolization (ineffective or accompanied by major complications) or there is no possibility for surgical intervention anymore. Only patients that have a normal clinical screening (no signs for infection, normal bone marrow function, normal liver and kidney function, normal glucose metabolism etc.) can be included.
• Patients included have no cardiac impairment
• Patients have no gastrointestinal impairment as Sirolimus is absorbed gastro-intestinal and normal function is needed
• No other underlying medical disorder like Down syndrome or other syndromes
• Women of reproductive age have to be informed that contraceptive methods are mandatory during the study time, pregnant women are excluded
• Karnofsky score > 50
|
|
E.4 | Principal exclusion criteria |
• No written informed consent
• Known hypersensitivity to drugs or metabolites from similar classes as study
treatment.
• Known hypersensitivity to drugs or metabolites from similar classes as study
treatment.
• Patient has other concurrent severe and /or uncontrolled medical condition that would, in the investigator’s judgment, contraindicated participation in the clinical study (e.g. acute or chronic pancreatitis, liver cirrhosis, active chronic hepatitis, severely impaired lung function with a spirometry ≤ 50% of the normal predicted value and/or O2 saturation ≤ 88% at rest, etc.)
• Recent history of primary malignancy ≤ 5 years
• Impaired cardiac function or clinically significant cardiac diseases
• Immunocompromised patients, including known seropositivity for HIV
• Patient with any other concurrent severe and /or uncontrolled medical condition that
would,in the investigator’s judgment, contraindicated participation in the clinical
study.
• Pregnant or lactating women
• Karnofsky score < 50
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Endpoints will be evaluated after a time period of six months treatment with Sirolimus:
Evaluation of Pain
Quality of Life
MRI of the vascular malformation |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Evaluation will be performed at time point zero:
pain evaluation
MRI of the vascular malformation
Quality of life assesment
And will subsequently re-evaluated after the treatment period of six months with sirolimus |
|
E.5.2 | Secondary end point(s) |
Will Sirolimus also inhibit growth/progression of the vascular malformation or even lead to reduction of the size of the vascular malformation?
Based on the case reports described in literature, there is a good chance that Sirolimus leads to regression of the vascular malformation. Although this is not the primary objective of the present study, we would like to gain more insight in the percentage of patients this effect can be seen. For this, MRI of the vascular malformation will be made at the beginning of the study and after six months of treatment with Sirolimus. An experienced radiologist will evaluate the evolution of the volume of the malformation
Are there genetic factors in the vascular malformation that can predict outcome of treatment with Sirolimus?
Further insight in genotype-phenotype-correlation for venous and/or lymphatic malformations might offer the possibility for better, personalized treatment. It is the question whether Sirolimus will have a positive effect in those patients were no mutation could be found in one of the known genes (PIK3CA/ GNAQ/ AKT-1/ RASA / PTEN/ TIE-2/ Glomulin) involved in vascular malformations. Depending on the results of the present study, we will investigate whether this can be used for further individualization of treatment.
Adverse events: short and long term consequences of treatment with Sirolimus
All adverse events occurring will be entered in the Castor Database and scored using the CTCAE criteria version four. Subsequently, at the end of the study all data will be analyzed in SPSS using Chi-square analyses.
Will the administration of Sirolimus lead to a more cost-effective treatment
One of the secondary objectives is to evaluate whether the administration of Sirolimus indeed leads to a more cost effective treatment for patients with venous and/or lymphatic malformation. For this reason a cost-effectiveness analysis will be performed from a societal perspective and in accordance with the Dutch guidelines for pharmaco-economic research. This analysis will be performed at te end of the study period of six months |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
During the fourth year of the study |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |